Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476151 | 0.92 | CTSS (0.42) | CTSSPKMSMN1; SMN2CAPN1CTSL | |
| SCHEMBL6475447 | 0.89 | CTSS (0.48) | CTSSPKMSMN1; SMN2CAPN1CTSL | |
| SCHEMBL6476747 | 0.87 | CTSS (0.45) | CTSSPKMSMN1; SMN2CAPN1 | |
| SCHEMBL6475446 | 0.85 | CTSS (0.48) | CTSSPKMSMN1; SMN2CTSLCTSK | |
| SCHEMBL6477138 | 0.85 | CTSS (0.44) | CTSSPKMSMN1; SMN2CTSLCTSK | |
| SCHEMBL6592927 | 0.85 | CTSS (0.35) | CTSSCTSLCTSK | |
| SCHEMBL6486213 | 0.84 | CTSS (0.45) | CTSSPKMSMN1; SMN2CAPN1CTSL | |
| SCHEMBL6482897 | 0.84 | CTSS (0.45) | CTSSPKMSMN1; SMN2CAPN1CTSL | |
| SCHEMBL6476174 | 0.83 | CTSS (0.41) | CTSSPKMSMN1; SMN2CAPN1CTSL | |
| SCHEMBL6476494 | 0.81 | CTSS (0.42) | CTSSPKMSMN1; SMN2CAPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSS 1/4885PKM 1974/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.